At what age are SABAs indicated for use?

Short-acting beta-agonists (SABAs) are typically indicated for use in children starting from the age of 4. This age threshold aligns with recommendations from asthma management guidelines, which suggest that when a child reaches 4 years of age, they are generally capable of using inhalers effectively under supervision, which is essential for the proper administration of SABAs.

At this age, children can often understand instructions and have better coordination for using inhalers, whether they are metered-dose inhalers or nebulizers, allowing for effective delivery of the medication to relieve acute asthma symptoms. Furthermore, guidelines emphasize that SABAs should be used primarily for quick relief of asthma symptoms and not as a long-term control medication, reinforcing the importance of appropriate usage as children age and their asthma management plans evolve.

In contrast, younger children, specifically those under 4 years of age, may have difficulties with inhalation techniques, making it challenging for them to benefit from SABA therapy effectively. Therefore, the appropriate age of 4 years for commencing the use of SABAs is based on the child's developmental readiness to use the medication effectively.